Meeting
2020 Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience.
Authors
William Schwartzman
UT Southwestern Medical Center, Dallas, TX
William Schwartzman , Roy Elias , Viral M. Patel , Alex Isaac Bowman , Suneetha Chintalapati , Payal Kapur , Hans J. Hammers , James Brugarolas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 640)
Abstract #
640
Poster Bd #
E4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah
Poster
2023 ASCO Annual Meeting
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
First Author: Kamaneh Montazeri
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey